EndeavorRx®: An FDA-Cleared Interactive, Nonpharmacologic Digital Therapeutic for Pediatric ADHD

In this discussion, EndeavorRx, a digital therapeutic indicated to improve
attention function in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue will be reviewed. The session will begin with an overview of Akili Interactive and focus on Prescription Digital Therapeutics engineered to treat cognitive impairments, that represents an entirely new category of medicine. This will be followed by a review of the key clinical attributes of EndeavorRx, relevant to the management of pediatric ADHD. Finally, the results of pivotal studies, including study design, key clinical endpoints, and safety profile of EndeavorRx will be presented.